Serum Bruton's tyrosine kinase and NF-κB in Hashimoto's thyroiditis ‒ a case-control study of potential diagnostic biomarkers

Authors

DOI:

https://doi.org/10.15584/ejcem.2026.2.17

Keywords:

autoimmunity, biomarkers, Bruton's tyrosine kinase, Hashimoto's thyroiditis, hypothyroidism, NF-κB

Abstract

Introduction and aim. Hashimoto's thyroiditis (HT) is the leading cause of hypothyroidism, yet its diagnosis relies on markers with known limitations. Bruton's tyrosine kinase (Btk) and nuclear factor kappa B (NF-κB) are implicated in B-cell-mediated autoimmunity. This study aimed to explore the serum levels and preliminary diagnostic potential of Btk and NF-κB in Iraqi patients with HT.

Material and methods. In this case-control study, 30 HT patients, 30 non-autoimmune hypothyroidism patients, and 60 healthy controls were enrolled from three centers in Karbala, Iraq. HT was defined by elevated TSH (>4.2 µIU/mL), reduced fT4 (<0.93 ng/dL), and positive anti-TPO and/or anti-Tg, whereas non-autoimmune hypothyroidism was defined by elevated TSH and low fT4 with negative thyroid autoantibodies. Serum Btk and NF-κB were measured by enzyme-linked immunosorbent assay. Thyroid hormones and autoantibodies were determined by electrochemiluminescence immunoassay. Receiver operating characteristic (ROC) analysis was performed to assess preliminary diagnostic accuracy for distinguishing HT from non-autoimmune hypothyroidism and healthy controls.

Results. Serum Btk and NF-κB levels were significantly elevated in HT patients compared to both control groups (Btk: 7.81±0.98 vs. 7.00±0.77 vs. 6.10±1.60 ng/mL; NF-κB: 1.90±0.71 vs. 0.91±0.21 vs. 0.84±0.39 ng/mL, p<0.001). In ROC analysis, NF-κB showed an area under the curve (AUC) of 0.95 (95% CI: 0.89–0.99) for discriminating HT from non-autoimmune hypothyroidism. Both biomarkers correlated positively with anti-TPO, anti-Tg, and TSH, and negatively with fT4.

Conclusion. Serum Btk and NF-κB were elevated in HT and showed preliminary associations with autoimmune activity. NF-κB, in particular, demonstrated promising initial diagnostic performance. These exploratory findings require validation in larger, independent cohorts.

Downloads

Download data is not yet available.

References

Vargas-Uricoechea H, Castellanos-Pinedo A, Urrego-Noguera K, Pinzón-Fernández MV, Meza-Cabrera IA, Vargas-Sierra H. A scoping review on the prevalence of Hashimoto's thyroiditis and the possible associated factors. Med Sci (Basel). 2025;13(2):43. doi:10.3390/medsci13020043

Kaur J, Jialal I. Hashimoto thyroiditis. StatPearls [Internet]. StatPearls Publishing; 2025.

Rydzewska M, Jaromin M, Pasierowska IE, Stożek K, Bossowski A. Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases. Thyroid Res. 2018;11(1):2. doi:10.1186/s13044-018-0046-9

Franco JS, Amaya-Amaya J, Anaya JM. Thyroid disease and autoimmune diseases. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, eds. Autoimmunity: From Bench to Bedside. Bogota, Colombia: El Rosario University Press; 2013.

Ralli M, Angeletti D, Fiore M, et al. Hashimoto's thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmun Rev. 2020;19(10):102649. doi:10.1016/j.autrev.2020.102649

Caturegli P, De Remigis A, Rose N. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13(4-5):391-397. doi:10.1016/j.autrev.2014.01.007

Murad R, et al. The role of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in assessing hypothyroidism Hashimoto's thyroiditis. Ital J Med. 2025;19(2). doi:10.4081/itjm.2025.1953

Bilge M, Adas M, Yesilova A, Helvaci A. Platelet-to-lymphocyte ratio and its association with Hashimoto's thyroiditis. Diseases. 2023;11(1):15. doi:10.3390/diseases11010015

Aktas G, Sit M, Dikbas O, et al. Could red cell distribution width be a marker in Hashimoto's thyroiditis? Exp Clin Endocrinol Diabetes. 2014;122(10):572-574. doi:10.1055/s-0034-1383564

Aktas G, Duman TT, Atak BM, et al. Irritable bowel syndrome is associated with novel inflammatory markers derived from hemogram parameters. J Med Biochem. 2020;39(1):62-66.

Bilgin S, Aktas G, Zahid Kocak M, et al. Association between novel inflammatory markers derived from hemogram indices and metabolic parameters in type 2 diabetic men. Aging Male. 2020;23(5):923-927. doi:10.1080/13685538.2019.1632283

Aktas G, Yilmaz S, Kantarci DB, et al. Is serum uric acid-to-HDL cholesterol ratio elevation associated with Hashimoto's thyroiditis? Rom J Intern Med. 2021;59(4):403-408. doi:10.2478/rjim-2021-0023

Aktas G, Yildirim M, Akbulut A, et al. HALP and SII indexes in Hashimoto's thyroiditis. Postgrad Med. 2026. doi:10.1080/00325481.2026.2621575

Crofford LJ, Nyhoff LE, Sheehan JH, Kendall PL. The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy. Expert Rev Clin Immunol. 2016;12(7):763-773. doi:10.1586/1744666X.2016.1152888

Mehra S, Nicholls M, Taylor J. The evolving role of Bruton's tyrosine kinase inhibitors in B cell lymphomas. Int J Mol Sci. 2024;25(14):7516. doi:10.3390/ijms25147516

Neys SF, Hendriks RW, Corneth OB. Targeting Bruton's tyrosine kinase in inflammatory and autoimmune pathologies. Front Cell Dev Biol. 2021;9:668131. doi:10.3389/fcell.2021.668131

Rip J, Van Der Ploeg EK, Hendriks RW, Corneth OB. The role of Bruton's tyrosine kinase in immune cell signaling and systemic autoimmunity. Crit Rev Immunol. 2018;38(1):17-62. doi:10.1615/CritRevImmunol.2018025184

Ringheim GE, Wampole M, Oberoi K. Bruton's tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. Front Immunol. 2021;12:662223. doi:10.3389/fimmu.2021.662223

Guo Q, Jin Y, Chen X, et al. NF-κB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024;9(1):53. doi:10.1038/s41392-024-01757-9

Giuliani C, Bucci I, Napolitano G. The role of the transcription factor nuclear factor-kappa B in thyroid autoimmunity and cancer. Front Endocrinol. 2018;9:471. doi:10.3389/fendo.2018.00471

Barnabei L, Laplantine E, Mbongo W, Rieux-Laucat F, Weil R. NF-κB: at the borders of autoimmunity and inflammation. Front Immunol. 2021;12:716469. doi:10.3389/fimmu.2021.716469

Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2(1):1-9. doi:10.1038/sigtrans.2017.23

Sun SC, Chang JH, Jin J. Regulation of nuclear factor-κB in autoimmunity. Trends Immunol. 2013;34(6):282-289. doi:10.1016/j.it.2013.01.004

Pontoriero M, Fiume G, Vecchio E, et al. Activation of NF-κB in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IκB-α. J Mol Med. 2019;97(5):675-690. doi:10.1007/s00109-019-01777-y

Sharma H, Kakadiya J. Different novel biomarkers involved in diagnosing hypothyroidism. Egypt J Intern Med. 2023;35(1):28. doi:10.1186/s43162-023-00211-2

Pempera N, Miedziaszczyk M, Lacka K. Difficulties in the diagnostics and treatment of Hashimoto's encephalopathy—a systematic and critical review. Int J Mol Sci. 2024;25(13):7101. doi:10.3390/ijms25137101

Tywanek E, Michalak A, Świrska J, Zwolak A. Autoimmunity, new potential biomarkers and the thyroid gland—the perspective of Hashimoto's thyroiditis and its treatment. Int J Mol Sci. 2024;25(9):4703. doi:10.3390/ijms25094703

World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO; 2000.

Qiao H, Mao Z, Wang W, et al. Changes in the BTK/NF-κB signaling pathway and related cytokines in different stages of neuromyelitis optica spectrum disorders. Eur J Med Res. 2022;27(1):96. doi:10.1186/s40001-022-00726-y

Liu Y, Zhu Z, Xu Q, et al. Identification of BTK as an immune-related biomarker for Hashimoto's thyroiditis by integrated bioinformatic analysis. BMC Immunol. 2025;26(1):11. doi:10.1186/s12865-025-00683-z

Yardim M, Deniz L, Saltabas MA, Celik N. Effect of thyroxine replacement therapy on serum maresin 1 and NF-kB levels in patients with Hashimoto thyroiditis. Diagnostics. 2025;15(10):1248. doi:10.3390/diagnostics15101248

Li X, Abdel-Mageed AB, Mondal D, Kandil E. The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers. Thyroid. 2013;23(2):209-218. doi:10.1089/thy.2012.0237

Ghazi SM, Salman AA, Jawad AA. Assessing cardiovascular changes in Iraqi women with hypothyroidism. J Med Life. 2023;16(4):579. doi:10.25122/jml-2023-0060

Petro JB, Rahman SJ, Ballard DW, Khan WN. Bruton's tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement. J Exp Med. 2000;191(10):1745-1754. doi:10.1084/jem.191.10.1745

Shinners NP, Carlesso G, Castro I, et al. Bruton's tyrosine kinase mediates NF-κB activation and B cell survival by B cell-activating factor receptor of the TNF-R family. J Immunol. 2007;179(6):3872-3880. doi:10.4049/jimmunol.179.6.3872

Garg N, Padron EJ, Rammohan KW, Goodman CF. Bruton's tyrosine kinase inhibitors: the next frontier of B-cell-targeted therapies for cancer, autoimmune disorders, and multiple sclerosis. J Clin Med. 2022;11(20):6139. doi:10.3390/jcm11206139

Mansour AA, Ali Alhamza AH, Abdullah Almomin AMS, et al. Patterns of thyroid disease in Basrah, Iraq: retrospective study. J Endocr Soc. 2020;4(Suppl 1):SUN-418. doi:10.1210/jendso/bvaa046.1128

Kargar S, Tabatabaei SM, Okati-Aliabad H, Rad HI. Prevalence of thyroid dysfunction disorders among adult populations in the Middle-East: a systematic review and meta-analysis. Open Public Health J. 2024;17(1). doi:10.2174/0118749445282227240115062556

Al-Zamali SKS, Jallod IMS, Mohammed SS, et al. Association between FOXP3 rs2232368 variant and Hashimoto's thyroiditis risk: a case-control study. Cureus. 2025;17(2). doi:10.7759/cureus.75421

Baranowska-Bik A, Bik W. The association of obesity with autoimmune thyroiditis and thyroid function—possible mechanisms of bilateral interaction. Int J Endocrinol. 2020;2020:8894792. doi:10.1155/2020/8894792

Bujnis M, DeSalvo K, Neklason DW, Madsen MJ, Jorde LB. Familial risk of Hashimoto's thyroiditis in a large genealogical database. J Clin Endocrinol Metab. 2025;110(12):e3998-e4003. doi:10.1210/clinem/dgaf023

Tulla S, Azaz S, Khan MSA. Evaluation of BMI in hypothyroid patients and its response to thyroxin therapy. Eur J Cardiovasc Med. 2022;12(4).

Mustafa MD, Tuama RM. The relationship between hypothyroidism and obesity. J Coast Life Med. 2022;10:73-84.

Song Rh, Wang B, Yao Qm, Li Q, Jia X, Zhang Ja. The impact of obesity on thyroid autoimmunity and dysfunction: a systematic review and meta-analysis. Front Immunol. 2019;10:443404. doi:10.3389/fimmu.2019.02349

Huo J, Xu Y, Yu J, et al. Causal association between body mass index and autoimmune thyroiditis: evidence from Mendelian randomization. Eur J Med Res. 2023;28(1):526. doi:10.1186/s40001-023-01520-0

Duntas LH, Biondi B. The interconnections between obesity, thyroid function, and autoimmunity: the multifold role of leptin. Thyroid. 2013;23(6):646-653. doi:10.1089/thy.2012.0524

Abdullah YJ, Essa RH, Jumaa MG. Incidence of Hashimoto's thyroiditis and its relationship to age, sex, smoking and blood groups. NTU J Pure Sci. 2022;1(2):1-9.

Downloads

Published

2026-05-06

How to Cite

Mohammed Abdul-Ridha Muhi, H., & Nusaif Al-Huchaimi, S. (2026). Serum Bruton’s tyrosine kinase and NF-κB in Hashimoto’s thyroiditis ‒ a case-control study of potential diagnostic biomarkers. European Journal of Clinical and Experimental Medicine. https://doi.org/10.15584/ejcem.2026.2.17

Issue

Section

ORIGINAL PAPERS